The goal of this observational study is to learn about the overall disease status, diagnostic and therapeutic modalities, and prognosis of patients with gastric cancer liver metastasis(GCLM) in China. The investigators divided the participants into three groups( three types) of gastric cancer liver metastasis based onChinese c-GCLM classification system.The main question it aims to answer is: 1. How long do patients with GCLM live? 2. How different treatment modalities (surgery, chemotherapy, immunotherapy, targeted therapy and others) affect patients' prognosis of three type? All participants will be tracked for their physical condition.
This is a prospective, non-interventional, observational, multi-centre, real-world study designed to monitor the general condition, treatment pattern and prognosis of patients with GCLM. GCLM patients were divided into 3 types: Type I (resectable type), Type II (potentially resectable type), Type III (unresectable type). The patients' general information, past medical history, imaging results, laboratory tests, surgical and systemic therapy details will be recorded and analysed. The 2-year overall survival (OS) will be recorded as the primary endpoint. The different therapies (surgery, chemotherapy and immunotherapy) of GCLM, the effects of different therapies on prognosis including OS of type I, II and III; R0 resection rate and diease free survival (DFS) of type I; successful conversion rate and R0 resection rate and events free survival (EFS) of type II will be recorded as secondary endpoints. This study involving human participants were reviewed and approved by the Ethics Committee of Chinese PLA General Hospital (No.S2023-724-02) and will be conducted according to the guidelines of the Declaration of Helsinki. Study findings will be disseminated through international peer-reviewed journal articles as well as public, academic presentations at national and international conferences.
Study Type
OBSERVATIONAL
Enrollment
1,326
This is an observational study.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
2-year OS
The primary study endpoint was two-year survival in patients
Time frame: 2 years OS from diagnosed time to measured time or death
OS of type I（questionnaires, phone calls, and outpatient follow-up.）
the effects of different therapeutic modalities (surgery, chemotherapy, immunotherapy, targeted therapy and others) on prognosis.
Time frame: OS from diagnosed time to measured time or death（up to 5 years）
OS of type II （questionnaires, phone calls, and outpatient follow-up.）
the effects of different therapeutic modalities (surgery, chemotherapy, immunotherapy, targeted therapy and others) on prognosis.
Time frame: OS from diagnosed time to measured time or death（2 to 5 years）
OS of type III（questionnaires, phone calls, and outpatient follow-up.）
the effects of different therapeutic modalities (surgery, chemotherapy, immunotherapy, targeted therapy and others) on prognosis.
Time frame: OS from diagnosed time to measured time or death（no more than 2 years）
DFS of type I（questionnaires, phone calls, and outpatient follow-up.）
DFS of type I. Disease-free survival time maintained after the participant has been saved by therapeutic measures.Especially in patients underwent radical surgery.
Time frame: Through study completion, an average of 2 year.
R0 resection rate (pathological information from medical record.)
Proportion of all operated patients achieving radical resection.
Time frame: Through study completion, an average of 2 year.
successful conversion therapy rate (pathological information and surgery information from medical record.)
Proportion of type II patients underwent radical surgery after systemic treatment.
Time frame: Through study completion, an average of 2 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.